Back |
home / stock / bsx / bsx message board
Subject | By | Source | When |
---|---|---|---|
Wild traders chart looking to breakout soon imho: | goldendayscom | investorshub | 09/20/2013 4:14:05 AM |
Looks like it is going to be brazils | goldendayscom | investorshub | 09/19/2013 3:18:26 AM |
Insider selling (at these prices) suggest threats to | benandemmiboo | investorshub | 09/12/2013 5:57:08 PM |
$BSX.TO - chart update | Tommy | investorshub | 09/02/2013 2:15:57 PM |
$BSX.TO - Belo Sun Releases Results for 74 | Tommy | investorshub | 07/24/2013 11:07:53 PM |
Corporate Overview | Tommy | investorshub | 07/06/2013 3:38:23 PM |
$BSX.TO - chart update | Tommy | investorshub | 07/06/2013 3:34:16 PM |
$BSX.TO - Fact Sheet | Tommy | investorshub | 07/06/2013 3:30:37 PM |
$BSX.TO - Presentation July 2013 | Tommy | investorshub | 07/06/2013 3:27:25 PM |
once permitting is resolved all lights are a go | moroDDstocks | investorshub | 04/18/2013 12:58:25 PM |
Fresh Releases - January 29, 2013 | canucklehead80 | investorshub | 01/31/2013 6:35:02 AM |
News, Short Squeeze, Breakout and More Instantly...
Boston Scientific Corporation Company Name:
BSX Stock Symbol:
NYSE Market:
Boston Scientific Corporation Website:
Shares of Boston Scientific Corporation (NYSE: BSX) traded at a new 52-week high today and are currently trading at $78.31. So far today, approximately 1.5M shares have been exchanged, as compared to an average 30-day volume of 5.37M shares. Boston Scientific Corporation develops, manufacture...
2024-07-08 14:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 09:15:03 ET Evercore ISI analyst issues OUTPERFORM recommendation for BSX on July 2, 2024 08:01AM ET. The previous analyst recommendation was Outperform. BSX was trading at $76.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...